JOHANNESBURG (Reuters) – Aspen Pharmacare reported flat full-year headline earnings on Tuesday, hit by higher acquisition-related transaction costs.
For the year to June 30, Africa’s biggest drugmaker recorded normalised headline earnings per share of 14.92 rand, largely unchanged from the 14.98 rand reported a year earlier.
The company declared a gross dividend of 359 cents per share, up 5%.
(Reporting by Nqobile Dludla; Editing by David Goodman)
Comments